Literature DB >> 18855606

Measurement of the endogenous adenosine concentration in humans in vivo: methodological considerations.

B P Ramakers1, P Pickkers, A Deussen, G A Rongen, P van den Broek, J G van der Hoeven, P Smits, N P Riksen.   

Abstract

The endogenous nucleoside adenosine has profound tissue protective effects in situations of ischaemia or inflammation. Animal studies have shown that various drugs can activate this protective mechanism by interfering with the metabolism of adenosine. Translation of this concept to the clinical arena is hampered by the difficulties encountered in measuring the adenosine concentration, due to the rapid cellular uptake and degradation of adenosine, which continues unabated after blood sampling, and due to the metabolically active endothelial barrier for adenosine. In the current paper, we critically discuss the various methods to measure the adenosine concentration in humans in vivo. For the measurement of circulating adenosine, we conclude that the use of a pharmacological blocker solution (containing inhibitors of the enzymes ecto-5'-nucleotidase, adenosine deaminase, and adenosine kinase, and of the equilibrative nucleoside transporter) and a purpose-built syringe which mixes the blood with this solution immediately at the tip of the needle, seems to be the most sensitive technique. However, for the measurement of adenosine concentrations in interstitial tissue, microdialysis is a suitable method, when used with an appropriate method to determine the recovery of adenosine across the semipermeable membrane to calculate the absolute adenosine concentration. Consistent use of these methods could help in the comparison of the various studies focussed on endogenous adenosine and could help to facilitate the use of drugs that modulate the adenosine concentration to protect tissues in the clinical arena.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855606     DOI: 10.2174/138920008786049249

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  22 in total

1.  A metabolomic, geographic, and seasonal analysis of the contribution of pollen-derived adenosine to allergic sensitization.

Authors:  Geoffrey A Mueller; Peter M Thompson; Eugene F DeRose; Thomas M O'Connell; Robert E London
Journal:  Metabolomics       Date:  2016-11-02       Impact factor: 4.290

Review 2.  The role of adenosine signaling in sickle cell therapeutics.

Authors:  Joshua J Field; David G Nathan; Joel Linden
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

3.  Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury.

Authors:  Bart P Ramakers; Niels P Riksen; Petra van den Broek; Barbara Franke; Wilbert H M Peters; Johannes G van der Hoeven; Paul Smits; Peter Pickkers
Journal:  Crit Care       Date:  2011-01-06       Impact factor: 9.097

4.  Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2.

Authors:  Carmelo Carmona-Rivera; Sami S Khaznadar; Kyawt W Shwin; Jorge A Irizarry-Caro; Liam J O'Neil; Yudong Liu; Kenneth A Jacobson; Amanda K Ombrello; Deborah L Stone; Wanxia L Tsai; Daniel L Kastner; Ivona Aksentijevich; Mariana J Kaplan; Peter C Grayson
Journal:  Blood       Date:  2019-04-23       Impact factor: 25.476

5.  The effect of adenosine deaminase inhibition on the A1 adenosinergic and M2 muscarinergic control of contractility in eu- and hyperthyroid guinea pig atria.

Authors:  Krisztian Pak; Judit Zsuga; Zita Kepes; Tamas Erdei; Balazs Varga; Bela Juhasz; Andras Jozsef Szentmiklosi; Rudolf Gesztelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-04-16       Impact factor: 3.000

6.  The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study.

Authors:  T N A van den Berg; Jaap Deinum; Albert Bilos; A Rogier T Donders; Gerard A Rongen; Niels P Riksen
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

Review 7.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

Review 8.  A review of the effects of ticagrelor on adenosine concentration and its clinical significance.

Authors:  Mohammed Ahmed Akkaif; Mei Li Ng; Muhamad Ali Sk Abdul Kader; Nur Aizati Athirah Daud; Abubakar Sha'aban; Baharudin Ibrahim
Journal:  Pharmacol Rep       Date:  2021-07-20       Impact factor: 3.024

9.  Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment.

Authors:  Yuesheng Li; Robert A Figler; Glynis Kolling; Tara C Bracken; Jayson Rieger; Ralph W Stevenson; Joel Linden; Richard L Guerrant; Cirle Alcantara Warren
Journal:  BMC Infect Dis       Date:  2012-12-10       Impact factor: 3.090

10.  Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo.

Authors:  T N A van den Berg; S El Messaoudi; G A Rongen; P H H van den Broek; A Bilos; A R T Donders; M E Gomes; N P Riksen
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.